{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-015873","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.542654+00:00","generated_at":"2026-06-26T04:26:41.749977+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Achieve Life Sciences reports positive Phase 3 ORCA-2 results; cytisinicline shows 6-8x odds of smoking abstinence","bullets":["Primary endpoints met: 12-week cytisinicline had 32.6% abstinence vs 7.0% placebo (OR 6.3, p<0.0001); 6-week had 25.3% vs 4.4% (OR 8.0, p<0.0001).","Secondary continuous abstinence weeks 9-24: 21.1% for 12-week arm vs 4.8% placebo (OR 5.3, p<0.0001); weeks 3-24: 8.9% vs 2.6% (OR 3.7, p=0.0016).","Well tolerated; no treatment-related serious adverse events. Most common AEs (>5%): insomnia, abnormal dreams, headache, nausea.","SVB approved remaining $10M of $25M debt facility; terms: interest at greater of 3.5% or WSJ prime, interest-only through Apr 2024, then 24-month amortization.","Facility available through Apr 30, 2023; no amounts drawn at close; discretionary draws allowed."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-015873","json":"https://secwatch.observer/filing/0001564590-22-015873.json","markdown":"https://secwatch.observer/filing/0001564590-22-015873.md","text":"https://secwatch.observer/filing/0001564590-22-015873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459022015873/0001564590-22-015873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459022015873/achv-8k_20220426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:26:41.749977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}